XML 58 R38.htm IDEA: XBRL DOCUMENT v3.20.4
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Summary of Stock Options Granted

3.The following table summarizes the activities for the Company’s stock options for the year ended December 31, 2020:

 

Year ended

December 31, 2020

 

Number

of options

Weighted

average

exercise

price

Weighted

average

remaining

contractual

term

(in years)

Aggregate

intrinsic

value

 

Outstanding at beginning of year

7,075,600

$

3.64

3.30

$

1,366

Granted

1,241,930

2.32

Exercised

(851,958

)

1.44

Forfeited or expired

(1,226,843

)

4.36

 

Outstanding at end of the year

6,238,729

$

3.52

3.17

$

2,654

 

Options exercisable at end of the year

4,017,763

$

4.05

2.19

$

1,938

 

Vested and expected to vest

5,806,504

$

3.59

3.02

$

2,502

Schedule of RSUs Granted

The following table summarizes the activities for the Company’s RSUs for the year ended December 31, 2020:  

Year ended

December 31, 2020

Number of

RSUs

Aggregate

intrinsic

value

 

Unvested at beginning of year

373,623

$

785

Granted

160,100

Vested

(188,603

)

Forfeited

(35,134

)

 

Unvested at end of the year

309,986

862

 

Vested and expected to vest

231,013

$

642

Summary of Stock Options And RSUs Granted Separated Into Ranges of Exercise Price

The following is a summary of the Company's stock options and RSUs granted separated into ranges of exercise price:

Exercise price

(range)

 

 

Options and RSUs

outstanding

as of

December 31, 2020

 

 

Weighted

average

remaining

contractual

life (years) for outstanding

options

 

 

Weighted

average

exercise

price

 

 

Options and RSUs

exercisable

as of

December 31, 2020

 

 

Weighted

average

remaining contractual life

(years) for exercisable

options

 

 

Weighted

average

exercise

price

$

 

 

 

 

 

 

 

 

$

 

 

 

 

 

 

 

 

$

 

RSUs 0.0

309,986

-

0.00

-

-

0.00

0.01-2.00

883,864

0.87

1.24

853,245

0.74

1.22

2.01-4.00

4,291,793

4.11

2.62

2,155,157

3.26

2.70

4.01-6.00

302,654

2.69

4.59

248,943

2.37

4.67

6.01-8.00

15,000

1.75

6.21

15,000

1.75

6.21

8.01-10.00

365,668

1.31

8.92

365,668

1.31

8.92

10.01-13.04

379,750

0.14

12.80

379,750

0.14

12.80

 

6,548,715

4,017,763

Schedule of Equity-Based Compensation Expense

The total equity-based compensation expense related to all of the Company's equity-based awards, recognized for the years ended December 31, 2018, 2019 and 2020, was comprised as follows:

Year ended

December 31,

2018

2019

2020

 

Cost of revenues

$

42

$

71

$

110

Research and development

313

366

243

Selling and marketing

640

708

545

General and administrative

985

908

764

 

Total share-based compensation expenses

$

1,980

$

2,053

$

1,662